Tirzepatide: What It Is and Its U.S. Regulatory Status

What is tirzepatide?

Tirzepatide is a synthetic peptide medicine developed by Eli Lilly, and it is an FDA-approved prescription drug. In the United States it is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea. Both are given once weekly under the skin, and it was the first approved medicine to activate both the GIP and GLP-1 receptors.

How it works

GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones the gut releases after meals. Both help the pancreas release insulin when blood sugar rises. GLP-1 also lowers glucagon, slows stomach emptying and reduces appetite, while the exact contribution of GIP to weight loss is still being studied. Tirzepatide is a 39-amino-acid peptide based on the GIP sequence, with a fatty acid side chain that binds albumin in the blood and gives it a half-life of about five days.

U.S. brands and approved uses

  • Mounjaro: approved on May 13, 2022 for blood sugar control in adults with type 2 diabetes, alongside diet and exercise. In December 2025 the FDA extended this to children aged 10 and older with type 2 diabetes, and in August 2026 it added reducing the risk of major cardiovascular events (cardiovascular death, heart attack or stroke) in adults with type 2 diabetes at high risk.
  • Zepbound: approved on November 8, 2023 for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition. On December 20, 2024 it became the first medicine approved for moderate to severe obstructive sleep apnea in adults with obesity.

Heart failure is not an approved use. Lilly filed for heart failure with preserved ejection fraction (HFpEF) based on the SUMMIT trial, but withdrew the application in 2025 after the FDA indicated that an additional trial was needed.

Key clinical trials

  • SURMOUNT-1: in 2,539 adults with obesity or overweight and no diabetes, average weight change at 72 weeks was up to minus 20.9% with the highest strength versus minus 3.1% with placebo.
  • SURMOUNT-OSA: two trials in 469 adults with moderate to severe sleep apnea and obesity. Breathing interruptions fell by about 27 to 30 events per hour at 52 weeks, versus about 5 to 6 with placebo.
  • SURMOUNT-5: in 751 adults with obesity and no diabetes, average weight change at 72 weeks was minus 20.2% with tirzepatide versus minus 13.7% with semaglutide.
  • SURPASS-CVOT: in 13,299 adults with type 2 diabetes and heart disease, tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% versus 13.1%, an 8% lower rate that did not reach superiority).
  • SURPASS-PEDS: in 99 young people aged 10 to 17 with type 2 diabetes, A1C fell by about 2 percentage points over 30 weeks.
  • SUMMIT: in 731 adults with HFpEF and obesity, tirzepatide lowered the risk of cardiovascular death or worsening heart failure by 38% versus placebo.

Label warnings

Mounjaro and Zepbound carry a boxed warning. Tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it causes these tumors, including medullary thyroid carcinoma, in humans. It must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2).

Other label warnings include pancreatitis, low blood sugar with insulin or insulin secretagogues, serious allergic reactions, kidney injury from dehydration, severe stomach and bowel reactions, worsening diabetic eye disease in people with a history of retinopathy, gallbladder disease and pulmonary aspiration during anesthesia or deep sedation. Tirzepatide can also make oral birth control pills less reliable for several weeks after starting it or moving up a strength. The most common side effects are nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion. After a January 2026 FDA request based on a review of 91 trials, Zepbound's suicidal thoughts warning was removed in February 2026. More detail: tirzepatide side effects.

U.S. regulatory status

Current status: FDA-approved prescription drug (Rx only).

The approval covers Lilly's branded products only. Tirzepatide was on the FDA drug shortage list from 2022 until the FDA declared the shortage resolved on October 2, 2024, a decision it reaffirmed on December 19, 2024 after a court review. Grace periods for compounders ended on February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities. Compounded tirzepatide is not FDA-approved, and the FDA has found fraudulent compounded tirzepatide carrying the names of pharmacies that did not make it. On April 30, 2026 it proposed excluding tirzepatide from the bulk substances list used by outsourcing facilities. Read more about compounded semaglutide and tirzepatide.

The FDA has also sent warning letters to companies selling tirzepatide falsely labeled "for research purposes" or "not for human consumption." Those products are not approved medicines, and their contents are unknown.

Sport

Semaglutide and tirzepatide are not on the World Anti-Doping Agency (WADA) 2026 Prohibited List. WADA's 2026 Monitoring Program tracks markers of both drugs in and out of competition to look for patterns of misuse in sport.

Why Peptide Labs does not sell tirzepatide

Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, and we do not provide prescription medicines of any kind.

If you have questions about tirzepatide or a related health concern, talk to a licensed healthcare provider who knows your medical history.

Related reading

See the full list of compound profiles in the Peptide Guide. Compare the two leading medicines in semaglutide vs tirzepatide, read our semaglutide profile, or see Lilly's newer pill in Foundayo (orforglipron). For an investigational successor, see retatrutide. For background, read what FDA-approved prescription drug means and our overview of peptides for weight loss.